Final Program

114 SUNDAY • MAY 15
A86
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
BRINGING ORDER TO THE CHAOS OF ACOS
(ASTHMA-COPD OVERLAP SYNDROME)
Assemblies on Allergy, Immunology and Inflammation; Clinical Problems;
Nursing; Respiratory Cell and Molecular Biology; Respiratory Structure
and Function
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2005/2007 (West Building, Level 2)
Target Audience
Physicians, basic scientists, physiologists, physician-scientists, clinical fellows and
residents, graduate and postdoctoral research trainees, and nurses interested in
asthma, COPD, and ACOS. This topic also has broader appeal for epidemiologists,
nurses, and respiratory therapists, given the significant clinical and public health
impact of this new syndrome/disease phenotype.
Objectives
At the conclusion of this session, the participant will be able to:
• understand the molecular, pathophysiological, and clinical features of ACOS
and use these criteria to distinguish ACOS from asthma or COPD;
• offer timely and appropriate diagnosis and treatment by recognizing ACOS
patients, their higher disease severity, and risk profile, while closely
monitoring patient outcomes;
• discuss and appreciate the significant heterogeneity and overlap between
asthma and COPD where ACOS serves as an emerging and important
clinical phenotype linking both diseases.
Some patients manifest an intermediate or overlapping phenotype of asthma and
COPD, i.e. the “asthma-COPD overlap syndrome” (ACOS). Yet, ACOS has
largely been ignored in clinical trials. ACOS comprises 15 to 55% of patients with
obstructive lung diseases, and manifests more symptoms, greater lung function
decline, increased risk of severe exacerbations, and possibly a reduced life span.
Such observations have spawned a recent and broad international interest in
ACOS. This session presents a comprehensive overview of ACOS in relation to
the controversial British and Dutch Hypotheses, and offers novel insights
regarding the genetic origins, pathogenesis, diagnosis, and treatment of ACOS.
Chairing: A.A. Zeki, MD, MAS, Sacramento, CA
K. Chung, MD, PhD, London, United Kingdom
M.J. Holtzman, MD, St. Louis, MO
2:15 How to Clinically Distinguish ACOS from Asthma and COPD
P.G. Gibson, MBBS, Newcastle, Australia
2:35 Shared Immunity in Asthma and COPD
M.J. Holtzman, MD, St. Louis, MO
2:55 Genetic Origins of ACOS
M.E. Hardin, MD, Boston, MA
3:15 Genomic and Molecular Phenotyping to Distinguish ACOS
from Asthma and COPD
P.G. Woodruff, MD, MPH, San Francisco, CA
3:35 Smoking in Asthma: An ACOS Phenotype?
K. Chung, MD, PhD, London, United Kingdom
3:55 Treatment of ACOS: Lessons From Clinical Studies in Asthma
and COPD
S.I. Rennard, MD, Melbourne, United Kingdom
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
A87
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
E-CIGARETTE VAPING: PRECLINICAL AND
CLINICAL PULMONARY HEALTH EFFECTS
Assemblies on Environmental, Occupational and Population Health;
Allergy, Immunology and Inflammation; Behavioral Science and Health
Services Research; Respiratory Cell and Molecular Biology; Respiratory
Structure and Function
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 130-132 (North Building, Lower Level)
Target Audience
Basic and translational/clinician scientists working on lung diseases. Lung
health researchers, nurses, pharmacists, users of e-cigarettes, smoking
cessasion professionals, manufacturers and retailers of e-cigarettes and
e-fluids/e-juices, students, fellows, residents with clinical, research, tobacco
control lobbyists, or people with health care and administrative responsibilities.
Objectives
At the conclusion of this session, the participant will be able to:
• learn about e-cigarettes vaping and flavorings pulmonary health
consequences;
• learn and understand the current clinical trials based on harm reduction,
perceptions, addictions, and environmental effects of vaping in suceptible
populations and patients with respiratory diseases;
• learn scientific debates and regulatory aspects on public and environmental
health and understanding the pulmonary and extrapulmonary effects of
vaping will provide insights on behavior, addiction, cessation and/or
aggravating pulmonary diseases and their exacerbations.
Electronic cigarettes (e-cigs) use flavored/non-flavored e-liquids/e-fluids, which
contain propylene glycol/glycerol (humectants), nicotine, and flavors (e.g. candy
flavors including sweeteners). These device generate aerosol containing
reactive oxygen species, aldehydes, ultrafine/nanoparticles, and heavy metal
particles. E-cig products are launched without the FDA approval, and an
increasing number of products are being launched every day without knowing
the harmful consequences. This symposium is aimed towards understanding
the pulmonary studies on e-cig exposure including biomarkers, inhalation and
basic preclinical/translational science, and host-innate response, as well as
clinical epidemiological studies for prediction of pulmonary health effects of
e-cigarette vaping and flavoring agents.
Chairing: I. Rahman, PhD, Rochester, NY
I. Jaspers, PhD, Chapel Hill, NC
S. Biswal, PhD, Baltimore, MD
B. Tomoko, MD, Tokyo, Japan
ATS 2016 • San Francisco